Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

NCT07363304 is registered in ClinicalTrials.gov with Meyer Children's Hospital IRCCS as lead sponsor.

NCT NCT07363304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07363304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Lead sponsor
Meyer Children's Hospital IRCCS
Phase
Observational
Overall status
Recruiting
Start date
December 2, 2025
Completion date
April 30, 2029
Enrollment
150 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf)